Abstract At high concentrations, the glutamine synthetase inhibitor L-methionine-S,R-sulfoximine (MSO) is a convulsant, especially in dogs. Nevertheless, sub-convulsive doses of MSO are neuroprotective in rodent models of hyperammonemia, acute liver disease, and amyotrophic lateral sclerosis and suggest MSO may be clinically useful. Previous work has also shown that much lower doses of MSO are required to produce convulsions in dogs than in primates. Evidence from the mid20th century suggests that humans are also less sensitive. In the present work, the inhibition of recombinant human glutamine synthetase by MSO is shown to be biphasic-an initial reversible competitive inhibition (K i 1.19 mM) is followed by rapid irreversible inactivation. This K i value for the human enzyme accounts, in part, for relative insensitivity of primates to MSO and suggests that this inhibitor could be used to safely inhibit glutamine synthetase activity in humans.
Introduction
Glutamine synthetase catalyzes the ATP-dependent condensation of ammonia 1 and glutamate to glutamine:
This enzyme plays unique roles in the biology of prokaryotes and eukaryotes. For example, prokaryotes utilize glutamine generated by glutamine synthetase to synthesize the cell walls that surround these organisms Horwitz 1999, 2003; Nilsson et al. 2009 ). The prokaryote glutamine synthetases are sufficiently different from the mammalian enzymes to have warranted significant research effort to produce antibacterial agents based on this difference (Krajewski et al. 2005 (Krajewski et al. , 2008 Nilsson et al. 2009 ). In the human brain, glutamine synthetase is found primarily in the astrocytes and acts to regulate ammonia concentrations and supply neurons with glutamine (Pamiljans et al. 1962; Martinez-Hernandez et al. 1977; Norenberg and Martinez-Hernandez 1979; Pow and Robinson 1994; Laake et al. 1995; Eisenberg et al. 2000; Kruchkova et al. 2001) . A portion of this pool of glutamine is subsequently converted to glutamate. Certain pathological states involve elevations in either ammonia or glutamate and therefore might benefit from regulation of glutamine synthetase. Elevations in cerebral ammonia result in increased levels of glutamine within astrocytes Cooper 2012a, b) . Glutamine is a significant osmolyte, and therefore, the increase in its concentrations adds to the brain swelling characteristic of hyperammonemia, particularly in the acute form of this condition (Desjardins et al. 1999; Tok et al. 2009; Brusilow et al. 2010; Mardini et al. 2011; Cudalbu et al. 2012) . Astrocytic glutamine contributes to excitotoxicity by acting as a precursor of the excitatory neurotransmitter glutamate (Ghoddoussi et al. 2010; Bame et al. 2012 ). These observations suggest that limiting the production of glutamine in astrocytes could mitigate the toxicity due to either hyperammonemia or glutamate excitotoxicity. Despite these possibilities, little information exists concerning the kinetic behavior of human glutamine synthetase or its regulation by specific inhibitors.
One possible inhibitor that might be used in humans to regulate either the endogenous or prokaryote forms of this enzyme is L-methionine-S,R-sulfoximine (MSO). A number of studies indicate that MSO is therapeutic in the treatment of hyperammonemia and glutamate excitotoxicity. For example, in an acute murine model of liver disease, the animals were protected by prior administration of MSO (Warren and Schenker 1964; Jambekar et al. 2011) . Similarly, the chronic administration of MSO in a murine model of amyotrophic lateral sclerosis (ALS) increased the survival time of the affected animals (Ghoddoussi et al. 2010; Bame et al. 2012) . The finding that MSO has therapeutic benefit in a model of ALS is particularly exciting because at present only one drug has been approved to treat this disease (Hardiman et al. 2011) . The drug-Riluzole-increases average life expectancy in ALS patients by a modest 3-6 months and comes with a risk of hepatic complications. Nevertheless, enthusiasm for the use of MSO in humans is tempered by the observation that, at high concentrations, this compound causes convulsions and eventually death in experimental animals (Mellanby 1946; Pollock 1949; Gershoff and Elvehjem 1951) . This ability of MSO to induce convulsions is exploited in some murine models of epilepsy (Boissonnet et al. 2012 (Boissonnet et al. , 2013 . In contrast, low doses of MSO may mitigate the onset of epileptic seizures (Sun et al. 2013) . Given the potential use of this inhibitor in humans, we sought to characterize the inhibition of human glutamine synthetase by MSO.
Materials
The materials for protein purification: CHT ceramic hydroxyapatite (Type II, 40 μm particle size); Bio-Rad protein assay; Amicon Ultra-4 Centrifugal Filter Units (50 KDa); and UltrogelACA44 were purchased from Bio-Rad, Millipore and the Pall Corporation, respectively. Sigma-Aldrich supplied all other reagents used in the studies described below.
Methods
Recombinant human glutamine synthetase was overexpressed in Escherichia coli cells and purified as described by Listrom et al. (1997) . Protein concentrations were determined using the Bio-Rad dye-binding assay and bovine serum albumin was used as a protein standard. A unit of enzyme activity (U) is defined as the amount of enzyme that catalyzes the formation of 1 μmol of glutamine per minute under standard assay conditions. Glutamine synthetase activity was assayed using a modification of the method of Kingdon et al. (1968) , which couples the formation of product ADP to the oxidation of NADH. The standard reaction mixture contained 10 mM imidazole-HCl, 100 mM KCl, 40 mM MgCl 2 , 0.3 mM EDTA, 12 mM phosphoenolpyruvate, 10 mM ATP, 20 mM L-glutamate, 0.25 mM NADH, 10 mU pyruvate kinase, 13.3 mU lactate dehydrogenase, and 10 mM NH 4 Cl at a final pH of 7.5 and a volume of 1 mL. This mixture was warmed to 37°C and the reaction was then initiated by the addition of enzyme. The oxidation of NADH to NAD + was continuously monitored as the loss of absorbance at 340 nm and quantified using the extinction coefficient 6.
.cm
.
Results
Recombinant human glutamine synthetase was purified as described by Listrom et al. (1997) and exhibited a specific activity of 17.9 U/mg with a 4.5 % recovery and 11.1-fold increase in specific activity. The purified protein migrated as a single band on SDS-PAGE with an estimated monomer M r of 45,000 (not shown). Mammalian glutamine synthetase exists as a decamer of two concentric pentameric rings (Krajewski et al. 2008) . The amounts of glutamine synthetase cited in the text refer to the decamer rather the monomer. A LineweaverBurk plot constructed from the reciprocal of initial rates versus the reciprocal of substrate concentration ( Fig. 1 , solid squares) indicated a K m value for L-glutamate of 1.67 mM, a V max of 16.0±1.26 μmole/min/mg and maximal turnover number of 11.1/s for this enzyme (Table 1) , comparable to the earlier measurements of Listrom et al. (1997) . The addition of MSO to the reaction mixtures caused an apparent increase in the K m of the enzyme for glutamate, but no change in V max , as shown in Figs. 1a (circles) in a manner consistent with competitive inhibition. A Dixon plot of these apparent K m values yielded a K i of 1.19 mM for the competitive inhibition of glutamine synthetase by MSO (Fig. 1b) . Thus, MSO initially binds competitively to human glutamine synthetase with an affinity similar to that of the natural substrate glutamate (c.f. K i MSÕ 1.19 mM & K m Glu~1.67 mM: Table 1 ). Studies with other mammalian forms of this enzyme indicate that glutamine synthetase becomes rapidly inactivated in the presence of MSO (Sellinger 1967; Tate et al. 1972; Griffith and Meister 1978; Meister 1980) . This is also the case for the recombinant human glutamine synthetase as shown in Fig 2. The inactivation is rapid. For example, the t 1/2 for inactivation of human glutamine synthetase due to 5 mM MSO, in the presence of 20 mM L-glutamate, is~25 s (Fig. 2) .
Discussion
MSO inhibits reaction 1 by two distinct mechanisms: competitive inhibition followed by irreversible inactivation. Competitive inhibition occurs subsequent to the binding of ATP to glutamine synthetase. Nucleotide binding increases the affinity of the enzyme for glutamate, which binds to the active site by way of its α carboxyl and amino groups (Eisenberg et al. 2000) . MSO has similarly placed carboxyl and amino groups and competes with glutamate for binding to the active site of glutamine synthetase ( Table 2 ). The competitive nature of this inhibition has been confirmed for all of the forms of the enzyme studied thus far, including the human enzyme (Table 2) .
MSO and glutamate are phosphorylated after binding to the enzyme (Tsuda et al. 1971) . Phosphorylation of the γ-carboxyl of glutamate renders the resulting intermediate susceptible to nucleophilic attack by NH 3 (Eisenberg et al. 2000 ). An attack on this intermediate by water is prevented by prior closure of the channel to the active site for amino acids by a flap consisting of Gly302-Phe303-His304-Glu305-Thr306 (Eisenberg et al. 2000; Krajewski et al. 2008) . These residues refer to human glutamine synthetase. Homologs of this flap are also present in the prokaryote and other eukaryote forms of this enzyme (Eisenberg et al. 2000; van Rooyen et al. 2011 ). In addition to occluding the amino acid channel, the flap forms a binding pocket for ammonium by the juxtaposition of flap residue Glu305 with Asp63 in the active site (Gill and Eisenberg 2001) . This binding pocket for ammonium, however, is not formed when MSO is bound to glutamine synthetase. Instead, the protonated sulfoximine N atom of MSO hydrogen bonds with a carboxylate oxygen of Glu305 and prevents the interaction with Asp63 ( The values shown are the means ± SD for three independent measurements. Where error bars are not shown the SD is less than the width of the symbol The inhibition of human glutamine synthetase by MSO is remarkable in that the K i value for the reversible inhibition is largest thus far reported among the enzymes investigated (Table 2) . Moreover, this value is three orders of magnitude greater than the K i values reported for the bacterial forms of the enzyme and supports the contention that MSO or its variants may be useful in treatment of tuberculosis. Indeed, Harth and Horwitz (1999) reported that the Mycobacterium tuberculosis glutamine synthetase is a 100 times more sensitive to inhibition by MSO than a mammalian glutamine synthetase. Unfortunately, M. tuberculosis rapidly develops resistance to MSO by upregulating three alternative forms of glutamine synthetase (Carroll et al. 2011 ) and later efforts to inhibit this group of enzymes have focused on the nucleotide binding sites (Krajewski et al. 2005; Nilsson et al. 2009 ). At present, it is not possible to account for the differences in competitive inhibition of the various eukaryotic glutamine synthetases by MSO, based on the available structural information. The published structures are of the enzymes complexed with MSO or a comparable inhibitor (Eisenberg et al. 2000; Krajewski et al. 2005 Krajewski et al. , 2008 Unno et al. 2006; van Rooyen et al. 2011) . In these studies, the position of MSO is apparently invariant and suggests conservation in the catalytic fold regardless of any sequence divergence in other parts of the enzyme (Eisenberg et al. 2000; Krajewski et al. 2008; van Rooyen et al. 2011) . The MSO was also phosphorylated. Thus, the reported structures reflect the conformation of the enzymes in an irreversibly-inhibited state rather than the competitivelyinhibited state.
One of the motivations for conducting the present studies, was to examine whether differences in the catalytic activity between the human and canine glutamine synthetases could account for sensitivity of dogs to the induction of convulsions by MSO. Given the potential use of MSO in humans it is important to understand why some mammals are more sensitive to the effect of this compound than others (Pollock 1949; Proler and Kellaway 1965; Rowe and Meister 1970; Griffith and Meister 1978) . Dogs are especially sensitive to MSO (Gershoff and Elvehjem 1951) and produce two forms of glutamine synthetase distinguished by size (Shin and Park 2004) . The reported K i values for the inhibition of the short and long forms of the canine glutamine synthetase are 0.067 and 0.124 mM, respectively (Shin and Park 2004) . These values are likely to be an underestimate of the actual K i for initial competitive inhibition of these enzymes (i.e., they overestimate the affinity for MSO), because they were derived using an 15 minute end-point assay. As can be seen from Fig. 2 , the human glutamine synthetase is substantially inactivated within 5 min. Inactivation by MSO is a common feature of eukaryote and prokaryote glutamine synthetases (Sellinger 1967; Tate et al. 1972; Griffith and Meister 1978; Meister 1980; Rhee et al. 1981; Maurizi and Ginsburg 1982; Kim and Rhee 1987) and indicates that end-point assays cannot be used to determine K i values for MSO. For this reason, the K i MSO reported for the Phormidium Laminosum glutamine synthetase (Blanco et al. 1989 ) is also liable to be in error. Crystallographic studies suggest that the active sites of the human and canine enzymes are identical and imply that the actual K i value for the competitive inhibition of the short canine glutamine synthetase is comparable to value obtained for the human enzyme. As discussed above, the reported structures for the canine and human glutamine synthetase represent these enzymes in an irreversibly-inhibited conformation and therefore cannot be used to infer information about the competitively-inhibited glutamine synthetases. Thus, the 2 Glutamine synthetase inactivated by MSO can be reactivated by certain non-physiological manipulations (Maurizi and Ginsburg 1982) . Alibhai et al. (1994) possibility that the sensitivity of dogs to MSO-induced convulsion is due a tighter binding of MSO to glutamine synthetase cannot be assessed with the currently available data.
MSO inhibits γ-glutamylcysteine synthetase as well as glutamine synthetase in in vitro studies (Richman et al. 1973; Griffith and Meister 1978) . γ-Glutamylcysteine synthetase catalyzes the rate-limiting step of glutathione biosynthesis (Franklin et al. 2009 ). Administration of MSO to rodents, however, did not alter the content of glutathione in the brains of these animals (Ghittoni et al. 1970; Palekar et al. 1975; Griffith and Meister 1978) . This lack of an effect of MSO on the activity of γ-glutamylcysteine synthetase in vivo presumably reflects the slow turnover of glutathione in the brain (Chang et al. 1997 ) and the fact that glutathione synthesis is driven by the availability of cysteine rather than that of glutamine (Jeitner and Lawrence 2001) . Taken together, these observations indicate that MSO preferentially depletes the brain of glutamine synthetase activity.
ALS is a particularly devastating neurodegenerative disorder (Hardiman et al. 2011) . The patients almost always die within 2-5 years of onset due to the pulmonary complications of this disease. As noted in the Introduction, Riluzole is the only drug approved for the treatment of ALS and its therapeutic benefits are relatively modest (Hardiman et al. 2011) . Riluzole slows the course of ALS, in part, by limiting neuronal glutamate release (Hardiman et al. 2011) . MSO also stems the release of glutamate by neurons (Somers and Beckstead 1990; Zou et al. 2010) . The recent reports of MSO improving both survival rates and locomotor activity in a murine model of ALS suggest that this agent could be used to treat ALS (Ghoddoussi et al. 2010; Bame et al. 2012) . MSO is tolerated well by humans (Newell et al. 1949; Pollock 1949 ) and as discussed below, unlikely to cause the hepatic damage reported in~10 % of patients taking Riluzole (Bensimon and Doble 2004) .
Another condition for which the administration of MSO may have therapeutic value is hyperammonemia. Elevated levels of brain ammonia can arise in a variety of disease states, including acute and chronic liver disease and inborn errors of the urea cycle Ghoddoussi et al. 2010; Cooper 2012a, b) . Accumulation of ammonia in turn leads to encephalopathy and in some cases death. The neurotoxicity due to hyperammonemia results, in part, from the excess production of glutamine and MSO decreases the amounts of this amino acid in vivo (Ghoddoussi et al. 2010) . Indeed, MSO protects against acute ammonia toxicity (Warren and Schenker 1964) and acute liver failure in rodents (Jambekar et al. 2011 ). Thus, MSO may by extension be of use in the treatment of hyperammonemia in human patients.
One objection to the use of MSO in human is the fact, at relatively high concentrations, it can cause seizures in a variety of experimental animals (Mellanby 1946; Pollock 1949; Gershoff and Elvehjem 1951; Proler and Kellaway 1965; Boissonnet et al. 2012 Boissonnet et al. , 2013 Sun et al. 2013) . It was the occurrence of these seizures that led to the discovery of MSO. Early in 20 th century many hunting dogs in the US and the UK exhibited running fits. These convulsions were eventually linked to the ingestion of biscuits made with agenized flour 3 (Mellanby 1946 ). The actual convulsant was later identified as the L,S-diastereoisomer of MSO (Manning et al. 1969; Rowe and Meister 1970) . Humans had, however, consumed products made from agenized flour for several decades with no apparent ill effects (Newell et al. 1949) . The tolerance of humans to MSO has been confirmed in several experimental studies (Pollock 1949; Krakoff 1961 ). In addition, Rhesus monkeys acutely treated with MSO exhibited a~60 % reduction in cerebral glutamine synthetase activity with no discernible neurological deficits . A sustained 85 % decrement in glutamine synthetase activity due to MSO, also caused no adverse effects in the mice treated with this agent (Blin et al. 2002) . These observations suggest that MSO is not harmful to primates and rodents at levels that reduce glutamine synthetase activity substantially, and therefore may be safe to use in humans.
